Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older…The purpose of this study is to learn about the long-term safety and effectiveness of the study drug, PF-04965842 in participants who previously participated in PF-04965842 AD Phase 3 trials. Recruiting Principal Investigator Vincent C. HoBody Locations and Systems DermatitisArea VancouverAge 12 and above
Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis…The purpose of this study is to evaluate the efficacy and safety of two dosage strengths of PF-04965842 (100 mg and 200 mg taken orally once daily) relative to placebo over 12 weeks of study participation. Recruiting Principal Investigator Vincent C. HoBody Locations and Systems DermatitisArea VancouverAge 12 and above
Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTENDThe purpose of this extension trial is to evaluate the long-term safety of tralokinumab in patients with atopic dermatitis. Recruiting Principal Investigator Sunil KaliaBody Locations and Systems DermatitisArea VancouverAge 18 and above
Efficacy and Safety Study of Mepolizumab in Subjects With Moderate to Severe Atopic Dermatitis This is a multicenter, randomized, double-blind, placebo-controlled, 2-arm, parallel-group study that will investigate the efficacy and safety of mepolizumab SC in adolescent and adult subjects with moderate to severe AD. Recruiting Principal Investigator Vincent C. HoBody Locations and Systems DermatitisArea VancouverAge 18-70
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3The purpose of this study is to demonstrate that tralokinumab in combination with topical corticosteroids (TCS) is superior to placebo in combination with TCS in treating moderate-to-severe atopic dermatitis (AD). Recruiting Principal Investigator Sunil KaliaBody Locations and Systems Dermatitis, EczemaArea VancouverAge 18 and above
Open-label Study of Dupilumab (REGN668/SAR231893) in Patients With Atopic DermatitisThis is an open label extension study for patients who participated in placebo-controlled dupilumab atopic dermatitis (AD) trials. The study primarily evaluates long term safety (adverse events) and immunogenicity.Closed for Recruitment Principal Investigator Vincent C. HoBody Locations and Systems DermatitisArea VancouverAge 18 and above
Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic…The purpose of this study is to evaluate the efficacy and safety of two dosage strengths of a new drug (PF-04965842) relative to placebo over 20 weeks of study participation. recruitment poster Closed for Recruitment Principal Investigator Vincent C. HoBody Locations and Systems DermatitisArea VancouverAge 12 and above
